Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.
- Underwriting agreement covers 1,838,524 expiring $1.25 options
- No underwriting fee from existing supportive shareholder
- Raises up to $2.3 million to fund AML, lung cancer, cardioprotection trials
- Funds strengthen balance sheet following $22.9 million from exercised options
- Shares issued exempt from shareholder approval under ASX rules
Underwriting Agreement Secures Critical Funding
Racura Oncology (ASX:RAC) has entered into an underwriting agreement with investor Dr AJ Robinson to cover the exercise of up to 1,838,524 remaining $1.25 Piggyback Options expiring on 29 May 2026. This move guarantees the company will raise approximately $2.3 million from these options, further bolstering its war chest for ongoing clinical development.
So far, over 18 million of the 20.1 million Piggyback Options have been exercised, generating nearly $22.9 million in funding. The underwriting ensures that any unexercised options at expiry will be converted into ordinary shares, with no underwriting fee payable to Dr Robinson, who previously provided $3.22 million in capital support last December. This continuity of backing reflects strong investor confidence in Racura's pipeline.
Capital to Accelerate Multiple Clinical Programs
The funds raised will directly support Racura's Phase 3 acute myeloid leukaemia (AML) trial, its Phase 1a/b lung cancer program targeting EGFR-mutant non-small cell lung cancer, and its anthracycline cardioprotection studies. These programs are central to Racura’s strategy to advance (E,E)-bisantrene, its lead asset that silences the MYC oncogene, a key driver in cancer progression.
Backing these clinical efforts is crucial given the recent momentum, including the enrolment of the first patient in the HARNESS-1 lung cancer trial and development of a novel blood test to monitor cardioprotective effects. Racura’s cash position, which stood at $19.38 million as of late April, is set to strengthen further with this capital injection, providing operational runway into 2027 strong cash backing.
Share Issuance and Regulatory Compliance
The shares issued under the underwriting will be allocated in accordance with ASX Listing Rule 7.2 Exception 10, meaning they will not require shareholder approval nor impact the company’s placement capacity under Listing Rule 7.1. This streamlines the capital raising process and avoids dilution concerns that often accompany equity issues.
The underwriting agreement includes standard termination clauses covering adverse market movements, regulatory hurdles, or material changes in the company’s financial or operational status. This safeguards both parties while maintaining flexibility should unforeseen risks arise.
Investor Confidence Anchors Clinical Progress
Racura’s Executive Chair Pete Smith expressed gratitude towards shareholders who converted options early, enabling uninterrupted progress of clinical trials. The underwriting by an existing investor who previously funded the HARNESS-1 trial underscores a vote of confidence in Racura’s clinical and patent advances, including recent intellectual property filings protecting (E,E)-bisantrene’s composition and mechanism of action MYC gene silencing.
With multiple clinical milestones on the horizon, including dose escalation in lung cancer and ongoing AML studies, the secured funding reduces financial uncertainty and supports Racura’s ambition to deliver meaningful oncology therapies.
Bottom Line?
Racura’s underwriting deal locks in vital capital to sustain its clinical momentum, but the final amount raised hinges on option exercises before expiry.
Questions in the middle?
- How many remaining options will be exercised before the 29 May expiry?
- What impact will the new capital have on timelines for AML and lung cancer trials?
- Could further investor support emerge if clinical data meet expectations?